ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
Jingmei Hsu(Cancer Research Institute), Selina M. Luger(University of Pennsylvania), Jennifer D. Morrissette(Hospital of the University of Pennsylvania), James K. Mangan(UC San Diego Health System), Martin Carroll(University of Pennsylvania), Alexander E. Perl(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), Nirav N. Shah(Medical College of Wisconsin), Noelle V. Frey(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), David Porter(University of Pennsylvania), Jianhua Zhao(Hospital of the University of Pennsylvania), Anita J. Kumar(University of Pennsylvania)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k